ArticleG3 (Bethesda, Md.)2020
Type I-F CRISPR-Cas Distribution and Array Dynamics in
Article in G3 (Bethesda, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Genomic characterization ofPathogens and global health · 2026Article
- The complexity of multiple CRISPR arrays in strains with (co-occurring) CRISPR systems.microLife · 2026Article
- CRISPR-Cas Systems: A Functional Perspective and Innovations.International journal of molecular sciences · 2025Review
- Important applications of DNA nanotechnology combined with CRISPR/Cas systems in biotechnology.RSC advances · 2025Review
- Review
- Expanded geographic distribution for twomSphere · 2024Article
- Distribution characteristics of theInfection and immunity · 2024Article
- Dynamics of CRISPR-mediated virus-host interactions in the human gut microbiome.The ISME journal · 2024Article
- Assessing spacer acquisition rates inFrontiers in microbiology · 2024Article
- Article
- Legionella pneumophila Cas2 Promotes the Expression of Small Heat Shock Protein C2 That Is Required for Thermal Tolerance and Optimal Intracellular Infection.Infection and immunity · 2022Article
- CRISPR-Cas systems are widespread accessory elements across bacterial and archaeal plasmids.Nucleic acids research · 2022Article
- Extensive epigenetic modification with large-scale chromosomal and plasmid recombination characterise the Legionella longbeachae serogroup 1 genome.Scientific reports · 2022Article
- Immune lag is a major cost of prokaryotic adaptive immunity during viral outbreaks.Proceedings. Biological sciences · 2021Article
- Legionella pneumophila CRISPR-Cas Suggests Recurrent Encounters with One or More Phages in the FamilyApplied and environmental microbiology · 2021Article
- Pruning and Tending Immune Memories: Spacer Dynamics in the CRISPR Array.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In bacteria and archaea, several distinct types of CRISPR-Cas systems provide adaptive immunity through broadly similar mechanisms: short nucleic acid sequences derived from foreign DNA, known as spacers, engage in complementary base pairing with invasive genetic elements setting the stage for nucleases to degrade the target DNA. A hallmark of type I CRISPR-Cas systems is their ability to acquire spacers in response to both new and previously encountered invaders (naïve and primed acquisition, respectively). Our phylogenetic analyses of 43
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.